with private labels only having a 6% share of Kenvue's product categories compared to a peer median of 10%. Additionally, Kenvue operates in extremely attractive end markets with structural ...

Kenvue (NYSE:KVUE) rose 3.3% after a slew of ... denied the judge's invitation to comment on the proposed label or issue a statement of interest, the regulator did attach a March 2023 epidemiology ...

Kenvue (NYSE:KVUE) shares may see some relief ... denied the judge's invitation to comment on the proposed label or issue a statement of interest, the regulator did attach a March 2023 ...

In April, Cote denied Kenvue's motion to dismiss one of the lawsuits on the grounds that the U.S. Food and Drug Administration's approval of Tylenol's label preempted any state law claims.

May 4, 20235:12 PM UTCUpdated ago Shares, priced at $22 apiece by Kenvue, were indicated to open nearly 14% above their offer price on the New York Stock Exchange. Sign up here. J&J on Wednesday ...

Wide-moat Kenvue reported solid first-quarter earnings ... we think brands in self care are a bit more resilient to private-label trade-down because they are sought out in times of poor health ...

Aug 30 (Reuters) - Johnson & Johnson JNJ.N on Wednesday forecast 12.5% growth in its annual adjusted profit after completing the separation of consumer health company Kenvue KVUE.N. J&J also said ...

Kenvue Inc defied volatile market conditions to price about 166 million shares at $22 per share, said the source, who requested anonymity as the discussions are confidential. The IPO values Kenvue ...